glp-1 agonists oral New Guidelines for Type 2 Diabetes in 2025 Anesthetic Considerations for Patients Taking

Gynecol Endocrinol (2023) 39(1):2181652

doi: 10.1016/S0021-9258(18)85474-6 [DOI] [Google Scholar] 9

Further, davalintide dose-dependently reduces body weight and fat mass in rats with approximately 2-fold greater efficacy than rat amylin (125)

Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects

DPP-4 inhibitors have the advantage of decreasing glucagon by augmenting levels of incretin hormones, particularly driving insulin secretion in hyperglycemia to avoid glucagon overproduction

doi: 10.1016/j.dsx.2020.01.009